The Multiple Myeloma Hub was pleased to speak with Hang Quach. We asked, How are BCMA-directed bispecific antibodies currently utilized in real-world practice for multiple myeloma?
We summarize key findings from the final analysis of the phase III GMMG-HD7 trial, evaluating the PFS benefit of Isa-RVd vs RVd in transplant-eligible patients…
/PRNewswire/ — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of…
Online resource for healthcare professionals, providing information, news & support relating to multiple myeloma
We summarize key findings from the final analysis of the phase III ALCYONE trial evaluating the efficacy and safety of D-VMP vs VPM in transplant-ineligible…
The MM Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
During the Multiple Myeloma Hub Steering Committee Meeting in April 2025, key opinion leaders met to discuss the implications of measurable residual disease (MRD) on…
The MM Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
The Multiple Myeloma Hub was pleased to speak with Hang Quach. We asked, How are BCMA-directed bispecific antibodies currently utilized in real-world practice for multiple…
The Multiple Myeloma Hub was pleased to speak with Hang Quach. We asked, How are BCMA-directed bispecific antibodies currently utilized in real-world practice for multiple…
Stay up to date with the latest developments in multiple myeloma with our live social media coverage from the EHA 2025 Congress, June 12–15, Milan,…
